0001209191-17-014560.txt : 20170224
0001209191-17-014560.hdr.sgml : 20170224
20170224210425
ACCESSION NUMBER: 0001209191-17-014560
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170222
FILED AS OF DATE: 20170224
DATE AS OF CHANGE: 20170224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Browne L Daniel
CENTRAL INDEX KEY: 0001597583
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 17639412
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BOULEVARD
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-22
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001597583
Browne L Daniel
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK
CA
94560
1
1
0
0
CEO and President
Common Stock
2017-02-22
4
S
0
9768
20.5556
D
200659
D
Common Stock
2017-02-22
4
S
0
1269
20.6961
D
199390
D
Common Stock
409
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan originally adopted by Mr. Browne on December 7, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $21.00. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.65 to $20.70. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
/s/ Gordon Ho, Attorney-in-Fact
2017-02-24